CNBX Pharmaceuticals Inc. (OTCMKTS:CNBX – Get Free Report) was the recipient of a significant decline in short interest during the month of May. As of May 29th, there was short interest totaling 293,249 shares, a decline of 88.5% from the May 14th total of 2,549,897 shares. Based on an average trading volume of 39,007,375 shares, the short-interest ratio is currently 0.0 days.
CNBX Pharmaceuticals Stock Performance
Shares of OTCMKTS:CNBX remained flat at $0.00 during trading on Tuesday. The stock had a trading volume of 3,610,023 shares, compared to its average volume of 34,504,793. CNBX Pharmaceuticals has a 12-month low of $0.00 and a 12-month high of $0.01.
About CNBX Pharmaceuticals
CNBX Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the research and development of synthetic cannabinoid-based drug candidates. The company’s proprietary platform applies medicinal chemistry techniques to design novel small-molecule analogs of naturally occurring cannabinoids, aiming to improve efficacy and safety compared with existing therapies. Its pipeline includes multiple preclinical compounds targeting neuropathic and chronic pain, with a goal of advancing these candidates through IND-enabling studies.
Headquartered in Costa Mesa, California, CNBX Pharmaceuticals collaborates with contract research organizations and academic partners to conduct pharmacology and toxicology studies as well as scale up manufacturing processes.
Featured Articles
- Five stocks we like better than CNBX Pharmaceuticals
- The Bank of Mom and Dad Is Booming—3 Stocks to Watch
- Corning Is Paving AI’s Future With Glass
- Why’s Amazon Suddenly Lagging the S&P 500, and Is It a Warning?
- Crypto Winter Is Here: 3 Stocks To Put On Ice This Summer
Receive News & Ratings for CNBX Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CNBX Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
